Scholarlink

Abstract <p>The United States Food and Drug Administration (USFDA) regulates and inspects pharmaceutical drug products for its current good manufacturing process (cGMP) and data governance. The Food and Drug Administration (FDA) aims to monitor all drug substances intended for marketing within the United States to ensure compliance with its safety, efficacy, purity, and quality standards. An evaluation of Inspection trends and FDA FORM 483 observations for biologics from 2010 to 2025 reveals persistent areas of regulatory concern, evolving inspectional priorities, and significant disruptions due to global events like the COVID-19 pandemic.</p> Objective <p>The purpose of the study is to offer impartial insights into regulatory trends and to identify any underlying issues contributing to a site's non-compliance status. The trends in the inspection and issuance of FORM 483 for biologics for the past 15 years were analyzed to understand the probability of resulting enforcement actions. The study also aims to guide the biologic manufacturers and provide preventive measures to overcome possible regulatory violations.</p> Method <p>Cross-sectional examination of Inspection data and FORM 483 citations published in public databases by the FDA for inspections under the Biologics, covering the period from January 2010 to August 2025, was selected for the study. All the related metadata was accessed from the FDA Inspection Dashboard and Inspection Observation page on the FDA website. The data was deeply analysed, tabulated and understood the Code of Federal Regulations (CFR) violations and their root cause.</p> Results <p>The data collected was thoroughly evaluated, summarized, and the most common violations were identified. From the study, it is evident that the frequent violations are related to cGMP issues, like failure to follow written Standard Operating Procedures (SOP), failure to maintain contemporaneous documentation, and not performing thorough investigation before batch release, corresponding to 34%, 21%, and 14%, respectively.</p> Conclusion <p>The trend in the inspections and FORM 483 is mainly on cGMP Violations. A complete understanding of the FDA inspection and the requirements for good biologic manufacturing process is a must. Following proper Data governance principles and maintaining an internal audit checklist, training of employees on both evolving technology and guidelines will make an effective change and possibly reduce enforcement actions. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive Analysis of FDA Form 483 Issued for Biologics from 2010 to 2025: Identifying Trends and Areas of Concern

  • 期刊论文

  • 发表日期：

    2026年1月12日

查看全文
  • Prarthana Radhakrishnan,
  • Dhanabal S.P,
  • Ganesh GNK

摘要

Abstract

The United States Food and Drug Administration (USFDA) regulates and inspects pharmaceutical drug products for its current good manufacturing process (cGMP) and data governance. The Food and Drug Administration (FDA) aims to monitor all drug substances intended for marketing within the United States to ensure compliance with its safety, efficacy, purity, and quality standards. An evaluation of Inspection trends and FDA FORM 483 observations for biologics from 2010 to 2025 reveals persistent areas of regulatory concern, evolving inspectional priorities, and significant disruptions due to global events like the COVID-19 pandemic.

Objective

The purpose of the study is to offer impartial insights into regulatory trends and to identify any underlying issues contributing to a site's non-compliance status. The trends in the inspection and issuance of FORM 483 for biologics for the past 15 years were analyzed to understand the probability of resulting enforcement actions. The study also aims to guide the biologic manufacturers and provide preventive measures to overcome possible regulatory violations.

Method

Cross-sectional examination of Inspection data and FORM 483 citations published in public databases by the FDA for inspections under the Biologics, covering the period from January 2010 to August 2025, was selected for the study. All the related metadata was accessed from the FDA Inspection Dashboard and Inspection Observation page on the FDA website. The data was deeply analysed, tabulated and understood the Code of Federal Regulations (CFR) violations and their root cause.

Results

The data collected was thoroughly evaluated, summarized, and the most common violations were identified. From the study, it is evident that the frequent violations are related to cGMP issues, like failure to follow written Standard Operating Procedures (SOP), failure to maintain contemporaneous documentation, and not performing thorough investigation before batch release, corresponding to 34%, 21%, and 14%, respectively.

Conclusion

The trend in the inspections and FORM 483 is mainly on cGMP Violations. A complete understanding of the FDA inspection and the requirements for good biologic manufacturing process is a must. Following proper Data governance principles and maintaining an internal audit checklist, training of employees on both evolving technology and guidelines will make an effective change and possibly reduce enforcement actions.